Case Reports in Oncology (Jan 2013)

Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

  • Laura Van Ginderachter,
  • Tony Cox,
  • Ria Drijkoningen,
  • Ruth Achten,
  • Eric Joosens,
  • Annelies Maes,
  • Koen Theunissen,
  • Jeroen Mebis

DOI
https://doi.org/10.1159/000346614
Journal volume & issue
Vol. 6, no. 1
pp. 45 – 49

Abstract

Read online

Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as described for all alkylating agents – there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.

Keywords